These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32432955)

  • 1. Is biologic treatment of hidradenitis suppurativa during the COVID-19 pandemic different from psoriasis biologic treatment?
    Rosi E; Pimpinelli N; Prignano F
    J Dermatolog Treat; 2022 Feb; 33(1):599. PubMed ID: 32432955
    [No Abstract]   [Full Text] [Related]  

  • 2. Biologic drugs during COVID-19 outbreak.
    Montesu MA; Biondi G; Sotgiu G; Sucato F; Satta R
    Int J Dermatol; 2020 Oct; 59(10):1293. PubMed ID: 32767379
    [No Abstract]   [Full Text] [Related]  

  • 3. Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis suppurativa, and acne/rosacea during the COVID-19 pandemic.
    Yim RM; Singh I; Armstrong AW
    Dermatol Online J; 2020 Oct; 26(10):. PubMed ID: 33147660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of patients with hidradenitis suppurativa during the COVID-19 pandemic: Risk and benefit of immunomodulatory therapy.
    Molinelli E; Diotallevi F; Simonetti O; Brisigotti V; Sapigni C; Radi G; Campanati A; Offidani A
    Dermatol Ther; 2020 Nov; 33(6):e14256. PubMed ID: 32860474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the COVID-19 pandemic on the course and management of chronic inflammatory immune-mediated skin diseases: What's the evidence?
    Patsatsi A; Kyriakou A
    Clin Dermatol; 2021; 39(1):52-55. PubMed ID: 33972053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-center survey of biologic use for inflammatory skin diseases during the coronavirus disease 2019 pandemic.
    Kado S; Kamiya K; Kishimoto M; Maekawa T; Kuwahara A; Sugai J; Komine M; Ohtsuki M
    J Dermatol; 2021 Dec; 48(12):1907-1912. PubMed ID: 34549456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Impact of the COVID-19 Pandemic on Immunomodulatory and Immunosuppressive Therapies in Dermatology: Patient and Physician Attitudes in Argentina].
    Zimman S; Cura MJ; Luna PC; Echeverría CM; Mazzuoccolo LD
    Actas Dermosifiliogr (Engl Ed); 2020 Nov; 111(9):806-807. PubMed ID: 32576376
    [No Abstract]   [Full Text] [Related]  

  • 8. No impact of immunomodulatory treatments on SARS-CoV-2 (COVID-19) vaccine outcomes: A cross-sectional analysis of biologic and small molecule inhibitors used for psoriasis and hidradenitis suppurativa patients from the Epic Cosmos database.
    Lee BR; Brostek AR; Kaffenberger BH
    J Am Acad Dermatol; 2024 Jul; 91(1):100-102. PubMed ID: 38490372
    [No Abstract]   [Full Text] [Related]  

  • 9. Biologics for patients affected by hidradenitis suppurativa in the COVID-19 era: data from a referral center of Southern Italy.
    Marasca C; Ruggiero A; Megna M; Annunziata MC; Fabbrocini G
    J Dermatolog Treat; 2022 Feb; 33(1):592. PubMed ID: 32403954
    [No Abstract]   [Full Text] [Related]  

  • 10. Hidradenitis suppurativa: The importance of virtual outpatient care during COVID-19 pandemic.
    Shah M; Naik HB; Alhusayen R
    J Am Acad Dermatol; 2020 Jul; 83(1):e81-e82. PubMed ID: 32360857
    [No Abstract]   [Full Text] [Related]  

  • 11. Surveillance of psoriatic patients on biologic treatment during the COVID-19 pandemic: A single-center experience.
    Polat Ekinci A; Pehlivan G; Gökalp MO
    Dermatol Ther; 2021 Jan; 34(1):e14700. PubMed ID: 33369063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paradoxical psoriasiform reactions during treatment with adalimumab for hidradenitis suppurativa: Real-life experience and therapeutic response to other biological drugs.
    Burzi L; Repetto F; Ribero S; Mastorino L; Quaglino P; Dapavo P
    Dermatol Ther; 2022 Dec; 35(12):e15866. PubMed ID: 36175129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe Acute Respiratory Syndrome Coronavirus 2 and the Use of Biologics in Patients With Psoriasis [Formula: see text].
    Ladda M; Lynde C; Fleming P
    J Cutan Med Surg; 2020; 24(6):625-632. PubMed ID: 32757760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Treatment With TNF-α Inhibitors for Hidradenitis Suppurativa During the COVID-19 Pandemic.
    Benesh G; Andriano TM; Babbush KM; Hosgood HD; Cohen SR
    J Cutan Med Surg; 2021; 25(4):446-448. PubMed ID: 33625899
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical management of psoriasis patients during the COVID-19 pandemic.
    Chat VS; Uppal SK; Kearns DG; Wu JJ
    J Dermatolog Treat; 2022 Mar; 33(2):1166-1167. PubMed ID: 32568009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of patients with hidradenitis suppurativa during the COVID-19 pandemic.
    Montero-Vilchez T; Martinez-Lopez A; Salvador-Rodriguez L; Molina-Leyva A; Arias-Santiago S
    Dermatol Ther; 2020 Nov; 33(6):e13875. PubMed ID: 32558071
    [No Abstract]   [Full Text] [Related]  

  • 17. Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations.
    Blaszczak A; Trinidad JCL; Cartron AM
    J Am Acad Dermatol; 2020 Jul; 83(1):e31. PubMed ID: 32283230
    [No Abstract]   [Full Text] [Related]  

  • 18. Hidradenitis suppurativa perspectives during the COVID-19 pandemic.
    Dovalovsky K; Puyana C; Tsoukas MM
    Clin Dermatol; 2023; 41(5):622-627. PubMed ID: 37657617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-COVID-19 measurements for hidradenitis suppurativa patients.
    Giamarellos-Bourboulis EJ; Bettoli V; Jemec GBE; Del Marmol V; Marzano AV; Prens EP; Tzellos T; Zouboulis CC
    Exp Dermatol; 2021 Jun; 30 Suppl 1(Suppl 1):18-22. PubMed ID: 34085330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The differentiating effect of COVID-19-associated stress on the morbidity of blood donors with symptoms of hidradenitis suppurativa, hyperhidrosis, or psoriasis.
    Henning MAS; Didriksen M; Ibler KS; Ostrowski SR; Erikstrup C; Nielsen K; Sækmose SG; Hansen TF; Ullum H; Thørner LW; Kaspersen KA; Mikkelsen S; Jemec GBE; Pedersen OB
    Qual Life Res; 2023 Oct; 32(10):2925-2937. PubMed ID: 37270451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.